Eugene Washington, MD, chancellor for health affairs at Duke University and president and CEO of the Duke University Health System, and Nancy Andrews, MD, PhD, dean of the Duke University School of Medicine, announced this week the launch of the Duke Clinical and Translational Science Institute (CTSI).
This Institute is an academic hub at Duke for accelerating the translation and implementation of scientific discoveries into health benefits for patients and communities. The Institute will be led by L. Ebony Boulware, MD, MPH, Vice Dean for Translational Sciences, Associate Vice Chancellor for Translational Research, Chief of the Division of General Internal Medicine, and co-Principal Investigator of Duke’s Clinical and Translational Science Award (CTSA) from the NIH. Dr. Boulware is chief of the Division of General Internal Medicine and a Professor of Medicine.
“Our goal is to serve as a catalyst for translational science by facilitating collaborations across Duke departments, institutes, schools, and the community that help us advance health together,” Boulware said.
The CTSI will be the administrative home for the Duke CTSA award and will oversee and integrate CTSA core services into the fabric of translational science at Duke. The CTSI replaces the Duke Translational Medicine Institute (DTMI), which has closed as a formal institute. The Duke Clinical Research Institute (DCRI), led by Eric Peterson MD, MPH, will continue as a separate, but collaborating unit. The Duke Clinical Research Unit (DCRU) will continue to be housed within the DCRI.
“Duke is uniquely positioned to facilitate translational science innovations,” Dr. Washington said. “The CTSI will create an ecosystem for research and education efforts across Duke Health, our campus, and our community. By fostering collaborations throughout Duke as well as with our patients and our broader community, I am confident the CTSI will speed the pace at which we move discoveries to public benefit.”